Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Down 16.8% in March

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 376,288 shares, a decline of 16.8% from the March 15th total of 452,420 shares. Based on an average daily trading volume, of 37,885 shares, the days-to-cover ratio is currently 9.9 days. Currently, 8.0% of the shares of the company are sold short.

Institutional Trading of Coeptis Therapeutics

A number of hedge funds have recently modified their holdings of COEP. Steward Partners Investment Advisory LLC lifted its position in shares of Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the period. Yorkville Advisors Global LP bought a new position in shares of Coeptis Therapeutics during the 3rd quarter worth about $140,000. Marshall Wace LLP bought a new position in shares of Coeptis Therapeutics during the 4th quarter worth about $259,000. State Street Corp lifted its holdings in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the period. Institutional investors own 13.88% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Coeptis Therapeutics Stock Performance

NASDAQ:COEP traded up $0.41 during trading hours on Friday, hitting $14.12. 12,233 shares of the company traded hands, compared to its average volume of 50,115. The stock has a market capitalization of $87.80 million, a price-to-earnings ratio of -4.74 and a beta of -0.44. Coeptis Therapeutics has a twelve month low of $6.26 and a twelve month high of $21.41. The firm has a 50-day moving average of $11.84 and a 200 day moving average of $13.98. The company has a current ratio of 4.16, a quick ratio of 4.16 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:COEP) last released its earnings results on Thursday, March 19th. The company reported ($0.12) EPS for the quarter. The company had revenue of $0.86 million for the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.